FDA Outlines its Approach to Artificial Intelligence Regulation
U.S. regulation of artificial intelligence (AI) in medical devices will involve cooperative work among multiple departments within the FDA. On March 15, the FDA released “Artificial Intelligence and Medical Products: How CBER, CDER, CDRH, and OCP are Working Together,” which outlines how the agency’s medical product centers plan to address the efforts required to protect public health while fostering responsible innovation in AI used in medical products and their development.
Ensuring Continued Availability of In-Vitro Diagnostics in UK, EU
Early diagnosis plays a critical role in patient outcomes, from enabli
Getting to Yes From FDA
As the co-founder and CEO of FastWave Medical and the founder of Medsider, I’ve spoken to entrepreneurs who have found the regulatory journey to be more collaborative than confrontational.
ISO 80369-7: Changing the Standard for Luer Connectors
ISO 80369 Part 7, the long-awaited replacement to ISO 594, introduced a number of changes to the standard governing dimensions and performance requirements of Luer connectors. Its publication in October 2016 capped a monumental change in the fundamental thinking surrounding devices that transfer liquids and gases in healthcare settings. Despite the Technical Committee’s desire to disrupt as little as possible surrounding the current practices with Luer connectors, ISO 80369-7 still makes many significant changes.
MasterControl Study: FDA, CPSC Recalls Up 115% Since 2018
MasterControl , a provider of quality and manufacturing software solutions for the life sciences industry, has released a new study analyzing five years of product recall data from the Food and Drug Administration (FDA) and Consumer Product Safety Commission (CPSC) showing that recalls have increased more than 115 percent since 2018.
FDA Clarifies Recommendations on Cardinal Health Monoject Recall
The new letter by FDA aimed to expand the recall notice to PCA pumps, which the original recall did not mention. It’s that gap in information that concerned FDA.
